WallStSmart

POMDOCTOR LIMITED American Depositary Shares (POM)vsScienture Holdings, Inc. (SCNX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

POMDOCTOR LIMITED American Depositary Shares generates 83620% more annual revenue ($399.92M vs $477,680). SCNX leads profitability with a 0.0% profit margin vs -53.2%. SCNX earns a higher WallStSmart Score of 33/100 (F).

POM

Avoid

28

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 4.5
Piotroski: 4/9

SCNX

Avoid

33

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.0Quality: 6.0
Piotroski: 4/9Altman Z: 0.19
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for POM.

SCNXUndervalued (+21.4%)

Margin of Safety

+21.4%

Fair Value

$0.57

Current Price

$0.36

$0.21 discount

UndervaluedFair: $0.57Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

POM1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
17.2%8/10

17.2% revenue growth

SCNX3 strengths · Avg: 10.0/10
Price/BookValuation
0.2x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
449.1%10/10

Revenue surging 449.1% year-over-year

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Areas to Watch

POM4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.51M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-149.49M2/10

Negative free cash flow — burning cash

SCNX4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$14.33M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Return on EquityProfitability
-0.1%2/10

ROE of -0.1% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : POM

The strongest argument for POM centers on Revenue Growth. Revenue growth of 17.2% demonstrates continued momentum.

Bull Case : SCNX

The strongest argument for SCNX centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 449.1% demonstrates continued momentum.

Bear Case : POM

The primary concerns for POM are EPS Growth, Market Cap, Return on Equity.

Bear Case : SCNX

The primary concerns for SCNX are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

POM profiles as a growth stock while SCNX is a hypergrowth play — different risk/reward profiles.

SCNX is growing revenue faster at 449.1% — sustainability is the question.

SCNX generates stronger free cash flow (-3M), providing more financial flexibility.

Monitor PHARMACEUTICAL RETAILERS industry trends, competitive dynamics, and regulatory changes.

Bottom Line

SCNX scores higher overall (33/100 vs 28/100) and 449.1% revenue growth. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

POMDOCTOR LIMITED American Depositary Shares

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Pomdoctor Limited, offers an online B2C portal to sell pharmaceutical products. The company is headquartered in Guangzhou, China.

Visit Website →

Scienture Holdings, Inc.

HEALTHCARE · PHARMACEUTICAL RETAILERS · USA

Scienture Holdings, Inc. (SCNX) is a biotechnology firm focused on developing advanced therapeutic solutions for neurological disorders, utilizing an innovative drug development pipeline backed by a skilled research team. With a strong emphasis on addressing unmet medical needs, Scienture is poised to enhance patient outcomes while navigating the complexities of regulatory pathways. The company’s dedication to scientific rigor and its strategic partnerships not only bolster its growth potential but also position SCNX as a significant contributor to advancements in global healthcare. As the demand for effective neurological treatments grows, Scienture aims to leverage emerging opportunities within the expanding healthcare landscape.

Want to dig deeper into these stocks?